These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12180310)

  • 1. [Treatment of chronic hepatitis C: side effects, tolerability and quality of life].
    Gournay J; Richou C
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B60-75. PubMed ID: 12180310
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of chronic hepatitis C in special groups].
    Bourlière M; Halfon P; Portal I
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B238-47. PubMed ID: 12180296
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of patients with chronic hepatitis C who have not been previously treated].
    Marcellin P; Boyer N
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B194-201. PubMed ID: 12180288
    [No Abstract]   [Full Text] [Related]  

  • 4. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection.
    Sulkowski MS; Wasserman R; Brooks L; Ball L; Gish R
    J Viral Hepat; 2004 May; 11(3):243-50. PubMed ID: 15117326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chronic hepatitis C: apart from antiviral treatment what other measures should be recommended?].
    Larrey D
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B283-90. PubMed ID: 12180302
    [No Abstract]   [Full Text] [Related]  

  • 6. [Probable cutaneous sarcoidosis associated with combined ribavirin and interferon-alpha therapy for chronic hepatitis C].
    Savoye G; Goria O; Herve S; Riachi G; Noblesse I; Bastien L; Courville P; Lerebours E
    Gastroenterol Clin Biol; 2000; 24(6-7):679. PubMed ID: 10962394
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon plus ribavirin: a cautionary note.
    Macedo G; Ribeiro T
    Am J Gastroenterol; 1999 Oct; 94(10):3087-8. PubMed ID: 10520894
    [No Abstract]   [Full Text] [Related]  

  • 8. [The influence of HCV infection and immunomodulating therapy (interferon-alpha and ribavirin) on the condition of minor salivary glands and oral mucosa].
    Sulka A; Simon K; Jeleń M; Piszko P
    Przegl Epidemiol; 2005; 59(2):455-66. PubMed ID: 16190554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of combined antiviral therapy with interferon alfa and ribavirin in chronic hepatitis C patients with extrahepatic manifestations].
    Zarebska-Michaluk D; Lebensztejn DM; Kryczka W
    Przegl Epidemiol; 2007; 61(3):551-8. PubMed ID: 18069393
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.
    Schaefer M; Schmidt F; Folwaczny C; Lorenz R; Martin G; Schindlbeck N; Heldwein W; Soyka M; Grunze H; Koenig A; Loeschke K
    Hepatology; 2003 Feb; 37(2):443-51. PubMed ID: 12540795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia.
    Ong JP; Younossi ZM
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S17-21. PubMed ID: 15468613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of growth factors with antiviral therapy for chronic hepatitis C.
    Curry MP; Afdhal NH
    Clin Liver Dis; 2005 Aug; 9(3):439-51, vii. PubMed ID: 16023976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 24 weeks of interferon-ribavirin therapy should not routinely be given to all hepatitis C patients.
    van Leeuwen DJ; Yee LJ; Langner RG
    Am J Gastroenterol; 2002 Feb; 97(2):497-8. PubMed ID: 11866304
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination treatment for hepatitis C can be hazardous in patients co-infected with HIV.
    Schvarcz R; Moberg L; Sönnerborg A
    Antivir Ther; 1998; 3(4):233-4. PubMed ID: 10682144
    [No Abstract]   [Full Text] [Related]  

  • 15. [New strategies for treatment of chronic hepatitis C].
    Rizzetto M
    Forum (Genova); 1999; 9(2 Suppl):1-11. PubMed ID: 11300125
    [No Abstract]   [Full Text] [Related]  

  • 16. Ribavirin-induced hemolytic anemia in chronic hepatitis C patients.
    Itoh Y; Okanoue T
    J Gastroenterol; 2004 Jul; 39(7):704-5. PubMed ID: 15293148
    [No Abstract]   [Full Text] [Related]  

  • 17. How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients.
    Kasahara A
    J Gastroenterol; 2004 Nov; 39(11):1125-6. PubMed ID: 15580413
    [No Abstract]   [Full Text] [Related]  

  • 18. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin.
    Hoofnagle JH; Ghany MG; Kleiner DE; Doo E; Heller T; Promrat K; Ong J; Khokhar F; Soza A; Herion D; Park Y; Everhart JE; Liang TJ
    Hepatology; 2003 Jul; 38(1):66-74. PubMed ID: 12829988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tongue hyperpigmentation during interferon-alpha and ribavirin therapy.
    Aguayo-Leiva I; Pérez B; Salguero I; Jaén P
    Eur J Dermatol; 2009; 19(3):291-2. PubMed ID: 19286489
    [No Abstract]   [Full Text] [Related]  

  • 20. Interferon + ribavirin combination therapy. Open new approach to treatment of patients with hepatitis C virus.
    Iino S
    Ital J Gastroenterol Hepatol; 1999 Apr; 31(3):216-7. PubMed ID: 10379483
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.